• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Aetna Innovation Labs research best practices

Article

The Aetna Innovation Labs were created to test specific initiatives, determine success rates and impact, and expand programs that show promise.

Aetna has created a dedicated team it calls the Aetna Innovation Labs to research the practices that have the greatest potential to improve patient outcomes or demonstrate measurable value to customers, healthcare providers or members. The labs will allow Aetna to test specific initiatives such as those related to disease prediction and intervention, determine success rates and impact across populations of members, and expand programs that show promise.

The marketplace is rapidly changing,” said Michael Palmer, head of the Aetna Innovation Labs. “Forces such as healthcare reform, emerging technologies and economic conditions are driving our need to constantly develop innovative and measurable programs to improve healthcare quality and reduce costs for our customers and members.”

Palmer joined Aetna from Accenture, where he was global managing partner of medical technology.

In one of its first projects, the Aetna Innovation Labs is working to make cancer care more effective, more affordable and safer by deploying technology including the eviti clinical decision-support program. The company is making eviti available through its data exchange and applications platform, iNexx, and launching the program in New York and New Jersey.

A second project being undertaken by the Aetna Innovation Labs combines “big data” provided by Aetna with a supercomputer-enabled platform from GNS Healthcare with the goal of analyzing it to rapidly discover what types of interventions drive better outcomes in those who are at-risk for metabolic syndrome, and for whom these interventions work best.

“Aetna Innovation Labs is currently focused on clinical and platform innovation and on improving member and provider engagement,” Palmer said. “But we are exploring a number of different areas that will drive value, from next-generation platforms, to telehealth and mHealth (mobile health), to genomics. We will likely also launch new businesses based on the work of Aetna Innovation Labs to both strengthen our core offerings and provide new capabilities to our customers.”

Go back to the Managed Healthcare Executive eNews newsletter.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.